Neurosplice Biosciences

NeuroSplice is a biotechnology company dedicated to the discovery and development of precision therapeutics for neurodegenerative disorders, with a primary focus on Amyotrophic Lateral Sclerosis (ALS). The company's core technology centers on identifying and targeting aberrant RNA splicing patterns that lead to the production of toxic protein isoforms or the loss of essential proteins. By leveraging a proprietary discovery platform, NeuroSplice identifies unique splice variants that serve as high-value therapeutic targets. Their approach aims to intervene at the molecular level to stabilize neuronal health and slow disease progression. Based on pioneering research from the University of Wollongong, the company is advancing a pipeline of small molecules and antisense oligonucleotides designed to correct these splicing defects.